Table 2.

Associations of the two polymorphisms and cancer risk

		mir-146a rs2910164							mir-196a2 rs11614913
		OR(95%CI)							OR(95%CI)
		No. of Comparisons	GG VS. CC	P	GCVS. CC	P	GG/GCVS. CC	P	No. of Comparisons	CCVS.TT	P	CT VS. TT	P	CC/CT VS. TT	P
Total	F	11	1.14(1.00-1.29)	0.048	1.07(0.97-1.19)	0.184	1.09(0.99-1.20)	0.082	10	1.17(1.06-1.29)	0.002	1.11(1.02-1.21)	0.018	1.13(1.04-1.23)	0.003
	R	11	1.19(0.96-1.48)	0.109	1.12(0.92-1.35)	0.256	1.12(0.94-1.33)	0.193	10	1.18(1.02-1.37)	0.027	1.11(1.02-1.22)	0.021	1.13(1.03-1.25)	0.010
Ethnicity
Asian	F	4	1.22(1.04-1.43)	0.013	1.08(0.96-1.22)	0.174	1.12(1.00-1.25)	0.053	5	1.18(1.03-1.35)	0.018	1.10(0.98-1.23)	0.096	1.13(1.01-1.25)	0.027
	R	4	1.33(0.99-1.77)	0.056	1.08(0.97-1.22)	0.176	1.15(0.98-1.34)	0.088	5	1.16(0.94-1.43)	0.175	1.10(0.98-1.23)	0.096	1.13(1.01-1.25)	0.027
Caucasian		7	1.00(0.81-1.23)	0.966	1.03(0.83-1.28)	0.776	1.01(0.82-1.24)	0.934	5	1.15(1.00-1.33)	0.047	1.12(0.98-1.29)	0.087	1.14(1.00-1.30)	0.051
	R	7	1.08(0.78-1.50)	0.643	1.30(0.83-2.05)	0.256	1.17(0.80-1.70)	0.418	5	1.20(0.96-1.51)	0.102	1.16(0.96-1.40)	0.116	1.19(0.97-1.46)	0.095
Tumor type
Breast	F	3	0.91(0.75-1.10)	0.311	0.95(0.81-1.11)	0.493	0.95(0.81-1.10)	0.471	4	1.25(1.09-1.43)	0.002	1.15(1.01-1.31)	0.033	1.19(1.05-1.34)	0.005
	R	3	0.91(0.75-1.09)	0.307	0.90(0.70-1.16)	0.424	0.92(0.75-1.12)	0.399	4	1.30(1.01-1.68)	0.041	1.17(0.98-1.40)	0.086	1.22(1.00-1.50)	0.053
Othera	F	8	1.36(1.15-.161)	0.000	1.17(1.03-1.34)	0.020	1.21(1.06-1.37)	0.004	6	1.09(0.95-1.26)	0.204	1.08(0.96-1.22)	0.206	1.09(0.97-1.21)	0.151
	R	8	1.44(1.10-1.89)	0.008	1.31(1.00-1.72)	0.047	1.30(1.03-1.64)	0.024	6	1.09(0.92-1.31)	0.324	1.08(0.96-1.22)	0.208	1.09(0.97-1.21)	0.152

F: Fixed-effects model, R: Random-effects model;

^aIncluding cancers of renal, thyroid, bladder, lung, hepatocellular, and prostate for SNP miR-146a rs2910164; and cancers of glioma, bladder, renal, gastric, hepatocellular, and lung for SNP miR-196a2 rs11614913